The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Investigators conducted a systematic review and meta-analysis to elucidate the efficacy and safety of cTBS for the treatment of auditory hallucinations in schizophrenia.

A shorter course of post-mastectomy radiation doesn't jeopardize a patient's chances of successful breast reconstruction, a ...

Methylene blue and red light therapy are showing promise for treating depression. Read on to learn how these therapeutics may ...

Recent research is painting a clearer picture of the link between the use of clozapine for schizophrenia and respiratory ...

The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

New drug offers hope for patients with Schizophrenia that has long eluded effective treatment. Read on to know more.

Millions of Americans are affected by psychosis, a condition that includes schizophrenia, bipolar disorder, and depression.

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...